哈药股份：拉西地平片通过仿制药一致性评价

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. has received approval for the supplementary application of Lercanidipine Tablets from the National Medical Products Administration, indicating successful consistency evaluation for the generic drug [1] Group 1: Company Announcement - Harbin Pharmaceutical Group Sanjing Ming Water Pharmaceutical Co., Ltd. received the approval notice for Lercanidipine Tablets [1] - The drug is a specific high-efficiency calcium ion antagonist primarily used for treating hypertension [1] - The company invested approximately 30.3 million RMB in the research and development of this drug [1] Group 2: Market Context - As of the announcement date, there are four production licenses for Lercanidipine Tablets in China, with two manufacturers having passed the consistency evaluation [1] - The domestic sales revenue for the drug is projected to be 260 million RMB in 2023 and 250 million RMB in 2024 [1]